Clinical trials: Progesterone
Breast Cancer, Metastasis
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
- Trial name
- NCT00371345
- Testing
- Dasatinib, Dasatinib 100 mg
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00577122
- Testing
- Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Nicotine Dependence, Nicotine Withdrawal
Progesterone and Brain Imaging Study
Male and female smokers were recruited to undergo 2 phases of smoking cessation. Each phase was 4 days long and involved 3 brain-imaging scans, blood draws and an intervention involving progesterone or a matched placebo.
- Trial name
- NCT01954966
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
In Vitro Fertilization
Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)
Prospective, open, randomised, parallel, multicentre, two arm trial comparing a new form of luteal support (S.C.) to an approved comparator (vaginal gel).
- Trial name
- NCT00827983
- Testing
- Progesterone
- Where
- 14 sites in Germany, Hungary and 3 more
- Volunteers
- 683 people
- Sponsor
- IBSA Institut Biochimique SA
Psychological Stress
Stress, Sex, and the Generalization of Fear
The impact of well-known risk factors for such disorders (stress, biological sex, anxiety-related dispositions) on fear generalization will be examined.
- Trial name
- NCT03786952
- Testing
- Stress immediately before learning in males, Stress 30 minutes before learning in males, Stress immediately before learning in females
- Where
- United States
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Ohio Northern University
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
This is a randomized control trial with an anticipated 36 participants diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive either progesterone (200 mg.
- Trial name
- NCT02187224
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC…
- Conditions
- Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer
- Trial name
- NCT04504916
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Breast Cancer
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00573755
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Brain Injuries
Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury
The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery.
- Trial name
- SyNAPSe (NCT01143064)
- Testing
- Progesterone, Lipid emulsion without progesterone
- Where
- 156 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- BHR Pharma, LLC
Postmenopausal Syndrome
Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism
Estrogen and progesterone are two main female sex hormones. When a woman goes through menopause, the body's production of estrogen and progesterone significantly decreases.
- Trial name
- Estrogen (NCT00565916)
- Testing
- Estrogen, Progesterone
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Infertility
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
The study to compare to the efficacy and safety of Crinone versus combination medication in infertile women receive frozen-thawed embryo transfer (FET) in artificial cycles (AC).
- Trial name
- NCT03858049
- Testing
- Crinone, Duphaston
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
This phase II trial studies how well pegylated liposomal doxorubicin hydrochloride and carboplatin followed by surgery and paclitaxel work in treating patients with stage II-III breast cancer that does not have estrogen…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT02315196
- Testing
- pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Invasive Breast Cancer
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer.
- Trial name
- NCT03212170
- Testing
- [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
Suicidal Ideation
Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
This within-person, crossover, 3-condition, placebo-controlled study compares the impact of three perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent…
- Trial name
- CLEAR-2 (NCT03498313)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Illinois at Chicago
Progesterone Induced Endometrial Receptivity
Comparison of Day 19 and Day 20 Artificial FET
In recent artificial frozen embryo transfers (FET) in which blastocysts vitrified on day 4 of culture and transferred on P+4, with blastocysts traditionally transferred on P+5, a high rate of implantation has been observed.
- Trial name
- NCT02788097
- Testing
- Progesterone supplementation
- Where
- Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Antalya IVF
Breast Cancer, Stage II Breast Cancer
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT01831076
- Testing
- Exemestane, Exemestane and tamoxifen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Cocaine Dependence
Progesterone Treatment for Cocaine-dependent Women: A Pilot Study
The purpose of this pilot treatment trial is to evaluate the efficacy of oral micronized PROG in cocaine-dependent women. Since we have shown (Evans \& Foltin, 2006) that oral micronized PROG attenuates the positive subjective…
- Trial name
- PROG (NCT00632099)
- Testing
- Oral micronized progesterone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- New York State Psychiatric Institute
Secondary Amenorrhea
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
- Trial name
- NCT00160199
- Testing
- PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Solvay Pharmaceuticals